scholarly journals Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society

Radiology ◽  
2021 ◽  
Vol 298 (3) ◽  
pp. 550-566
Author(s):  
Takeshi Johkoh ◽  
Kyung Soo Lee ◽  
Mizuki Nishino ◽  
William D. Travis ◽  
Jay H. Ryu ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Clinical Management ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Chest Ct ◽  
Position Paper ◽  
Molecular Targeting ◽  
Ct Diagnosis ◽  
Molecular Targeting Agents

scholarly journals Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management

Cancer ◽  
2018 ◽  
Vol 124 (6) ◽  
pp. 1111-1121 ◽  
Author(s):  
Romualdo Barroso-Sousa ◽  
Patrick A. Ott ◽  
F. Stephen Hodi ◽  
Ursula B. Kaiser ◽  
Sara M. Tolaney ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Clinical Management ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Endocrine Dysfunction ◽  
Practical Recommendations

Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma

2017 ◽  
Vol 35 (6) ◽  
pp. 618-622 ◽  
Author(s):  
Naoshi Nishida ◽  
Masatoshi Kudo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Molecular Targeting ◽  
Advanced Hepatocellular Carcinoma ◽  
Targeting Therapy ◽  
Molecular Targeting Therapy

With the development of molecular targeting therapy, several treatment options for advanced hepatocellular carcinoma (HCC) have become available in cases where curative and other palliative treatments, such as radiofrequency ablation, surgical resection, and transarterial chemoembolization, are not applicable. However, with the detection of a variety of mutations in cancer-related genes in a single tumor, molecular heterogeneity is commonly observed in HCC. Therefore, mutations in the major cellular signaling pathways underlie the development of resistance to molecular targeting agents. On the contrary, immune checkpoint inhibitors have proven effective in patients who are refractory to conventional treatments and molecular targeting therapy. Several clinical trials are currently investigating the efficacy of immune checkpoint inhibitors both individually and in combination with other types of anticancer agents. In this review, we focus on the potential of immune checkpoint blockade in the treatment of human HCC.

scholarly journals Endocrine dysfunctions during treatment of immune-checkpoint inhibitors

2018 ◽  
Vol 2 (2) ◽  
Author(s):  
Hidefumi Inaba ◽  
Hiroyuki Ariyasu ◽  
Hisako Okuhira ◽  
Yuki Yamamoto ◽  
Hiroaki Akamatsu ◽  
...  
Keyword(s):  
Thyroid Gland ◽  
Adverse Effects ◽  
Pituitary Gland ◽  
Immune Checkpoint ◽  
Clinical Management ◽  
Immune Checkpoint Inhibitors ◽  
Adrenal Glands ◽  
Malignant Tumors ◽  
Checkpoint Inhibitors ◽  
Novel Agents

Immune-checkpoint inhibitors (ICIs) are novel agents directed to various malignant tumors. During ICI therapy, however, immune related adverse effects (irAEs) including endocrine dysfunctions have been reported. Dysfunctions in the pituitary gland and the thyroid gland by ICI are often observed, and those in the adrenal glands and the pancreas are less frequent. Positive correlation of the prevalence of endocrine irAEs to clinical antitumor effectiveness during ICI therapy has been reported. The mechanisms of endocrine irAEs by ICI, however, remain unclear, and optimal prevention, prediction, and treatment of the irAEs are still uncertain. This review describes possible mechanisms involved in ICI-related immunity, and discusses clinical management of endocrine irAEs during ICI therapy.

Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life

2021 ◽  
pp. 1-6
Author(s):  
Shuji Hiramoto ◽  
Tomohiko Taniyama ◽  
Ayako Kikuchi ◽  
Tetsuo Hori ◽  
Akira Yoshioka ◽  
...  
Keyword(s):  
Advanced Cancer ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Cancer Site ◽  
Molecular Targeting ◽  
Primary Cancer ◽  
Related Factors ◽  
Primary Cancer Site ◽  
Ecog Ps ◽  
Molecular Targeting Agents

Abstract Background In recent years, the use of both molecular targeting agents (MTAs) and immune-checkpoint inhibitors (ICIs) tend to occupy important positions in systemic anticancer therapy (SACT). The objective of this study is to describe the predictors of SACT include both MTAs and ICIs near the end of life (EOL) and the effect on EOL care in patients with advanced cancer. Methods We analyzed all patients who died of advanced cancer from August 2016 to August 2019, and we analyzed the survival time of patients who underwent anticancer agents excluded due to the loss of information about the last administration of SACT. The primary endpoint of this study was to identify predictors during the last administration of SACT near EOL. Results In a multivariate analysis, the Eastern Cooperative Oncology Group performance status (ECOG-PS) (ORs 33.781) was significantly related factors within 14 days of death from the last administration of SACT. Age (ORs 0.412), ECOG-PS (ORs 11.533), primary cancer site of upper GI cancers (ORs 2.205), the number of comorbidities (ORs 0.207), MTAs (ORs 3.139), and ICIs (ORs 3.592) were significantly related factors within 30 days of death. The median survival time (MST) of patients with PS 3–4 was 29 days, while that of patients with both PS 0–2 was 76 days. The prevalence rate of delirium with MTAs was 17.5%, which was significantly lower than that of patients without it (31.8%). The prevalence rate of the mean dose of opioids in patients with ICIs was 97.9 mg/day, which was significantly higher than that of patients without it (44.9 mg/day). Conclusions Age, ECOG-PS, primary cancer site, the number of comorbidities, MTAs, and ICIs use were significant associated with SACT near EOL. Information on these factors may aid clinical decision making in referral to palliative care institutes.

scholarly journals Endocrine dysfunctions during treatment of immune-checkpoint inhibitors

2020 ◽  
Vol 4 (1) ◽  
pp. 18
Author(s):  
Hidefumi Inaba ◽  
Hiroyuki Ariyasu ◽  
Hisako Okuhira ◽  
Yuki Yamamoto ◽  
Hiroaki Akamatsu ◽  
...  
Keyword(s):  
Thyroid Gland ◽  
Adverse Effects ◽  
Pituitary Gland ◽  
Immune Checkpoint ◽  
Clinical Management ◽  
Immune Checkpoint Inhibitors ◽  
Adrenal Glands ◽  
Malignant Tumors ◽  
Checkpoint Inhibitors ◽  
Novel Agents

Immune-checkpoint inhibitors (ICIs) are novel agents directed to various malignant tumors. During ICI therapy, however, immune related adverse effects (irAEs) including endocrine dysfunctions have been reported. Dysfunctions in the pituitary gland and the thyroid gland by ICI are often observed, and those in the adrenal glands and the pancreas are less frequent. Positive correlation of the prevalence of endocrine irAEs to clinical antitumor effectiveness during ICI therapy has been reported. The mechanisms of endocrine irAEs by ICI, however, remain unclear, and optimal prevention, prediction, and treatment of the irAEs are still uncertain. This review describes possible mechanisms involved in ICI-related immunity, and discusses clinical management of endocrine irAEs during ICI therapy.

Sign in / Sign up

Export Citation Format

Share Document